DarioHealth Corp. financial statements

Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data DarioHealth Corp. files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	2.8	5.17	7.39	7.56	7.58	20.5	27.7	20.4	27	22.4
Cost of revenue	3.36	3.86	5.63	4.96	5.06	16.6	18	14.4	13.8	9.69
Gross profit	-0.83	1.31	1.77	2.6	2.51	3.96	9.66	5.98	13.3	12.7
Research and development	2.15	3.3	3.68	3.69	4.43	17.2	19.6	20.2	24.2	13.8
Selling and marketing	4.74	7.71	10.3	11.1	15.2	39.7	30.3	23.8	26.4	20.3
General and administrative	3.38	4.73	5.47	5.48	12.8	23.5	16.5	18.1	20.5	15.2
Operating expenses	10.3	15.7	19.5	20.3	32.4	80.5	66.5	62.2	71	49.3
Operating income	-11.1	-14.4	-17.7	-17.7	-29.9	-76.5	-56.8	-56.2	-57.7	-36.7
Interest expense							1.88			3.02
Interest income			0	0.02	0.06	0.04	0.51	1.87	1.12	0.94
Other non-operating income	0.21	-1.32	-0.12	-0.03	0.46	-0.24	-5.38	-3.17	13.1	-4.95
Pre-tax income	-10.9	-15.7	-17.8	-17.7	-29.4	-76.7	-62.2	-59.4	-44.6	-41.6
Income tax						0.03	0	0.06	-1.85	0.11
Income from continuing operations									42.7	41.7
Net income	-10.9	-15.7	-17.8	-17.7	-29.4	-76.8	-62.2	-59.4	-42.7	-41.7
EBITDA	-10.7	-14.2	-17.5	-17.5	-29.7	-76.2	-56.5	-55.7	-56.4	-36.3
EPS, basic	842.41	661.03	314.39	160.92	80.66	81.87	51.09	38.82	12.27	10.12
EPS, diluted	842.41	661.03	314.39	160.92	80.66	81.87	51.09	38.82	12.27	10.12
Shares, basic (weighted)	0.01	0.02	0.06	0.11	0.3	0.82	1.18	1.41	2.45	3.98
Shares, diluted (weighted)	0.01	0.02	0.06	0.11	0.3	0.82	1.18	1.41	2.45	3.98

Balance sheet

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	1.09	3.72	11	20.4	28.6	35.8	49.4	36.8	27.8	21.8
Short-term investments	0.23	0.26								4.21
Receivables	0
Inventory	0.89	1.18	1.38	1.41	2.29	6.23	7.96	5.06	4.75	4.32
Other current assets	0.06	0.15	0.07	0.04	0.08	0.08	0.24	0.25	0.29	0.53
Total current assets	2.94	6.05	13.1	22.9	34.1	45.6	65.5	47.3	40.5	35.1
Property, plant and equipment	0.9	0.87	0.73	0.65	0.58	0.7	0.79	0.9	0.71	0.55
Lease right-of-use assets			0	0.77	0.5	0.29	1.21	0.97	1.07	0.72
Goodwill					0	41.6	41.6	41.6	57.4	57.4
Intangible assets						12.5	9.92	5.4	18.8	15.9
Total assets	3.87	6.96	14.1	24.6	35.4	101	119	96.4	119	110
Accounts payable	1.81	1.85	2.57	1.66	2.48	5.11	2.32	1.13	3.05	2.93
Accrued liabilities	0.62	0.43	0.88	0.89	0.88	4.4	2.19	2.23	1.94	2.4
Deferred revenue	0	0	0.74	1.22	1.22	1.2	1.32	1	1.58	0.71
Short-term debt						0	8.82	3.95	5.45
Total current liabilities	2.93	3.02	5.16	5.22	7.03	14.4	19.4	12.5	16.6	9.32
Long-term debt						0	18.1	24.6	23.5	30.7
Lease liabilities			0	0.46	0.22	0.02	0.83	0.89	0.77	0.57
Other non-current liabilities							0	0.04	0.03	0.05
Total liabilities	10.4	3.02	5.16	5.68	7.26	15.2	39.2	38.2	46.9	42.2
Total debt						0	26.9	28.5	28.9	30.7
Paid-in capital	48.4	74.9	98.2	129	171	308	366	408	462	520
Retained earnings	-55	-71	-89.3	-110	-143	-222	-286	-349	-390	-452
Shareholders' equity	-6.54	3.94	8.93	18.9	28.2	85.5	80	58.1	72	67.9
Total equity	-6.54	3.94	8.93	18.9	28.2	85.5	80	58.1	72	67.9
Total liabilities and equity	3.87	6.96	14.1	24.6	35.4	101	119	96.4	119	110
Shares outstanding	0.01	0.03	0.09	0.11	0.4	0.82	1.28	1.35	1.92	6.91

Cash flow statement

	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-10.9	-15.7	-17.8	-17.7	-29.4	-76.8	-62.2	-59.4	-42.7	-41.7
Depreciation and amortization	0.39	0.2	0.21	0.18	0.19	0.28	0.36	0.47	1.33	0.31
Stock-based compensation	1.04	3.82	3.76	2.32	11.1	25	17	19.7	0.05	9.37
Deferred income tax									-2
Change in inventory	-0.29	-0.3	-0.19	-0.04	-0.88	-2.23	-1.73	2.89	0.31	0.44
Cash from operations	-8.38	-10.6	-11.5	-15.7	-17.7	-50.4	-47.8	-30.4	-38.6	-25.9
Capital expenditures	-0.81	-0.2	-0.07	-0.1	-0.12	-0.26	-0.44	-0.58	-0.14	-0.14
Acquisitions									-8.8
Purchases of investments	-0.15	-0.02
Cash from investing	-0.95	-0.22	-0.07	-0.11	-1.62	-8.13	-0.57	-0.55	-8.93	-4.34
Debt repaid								-27.8		-31.5
Stock issued					27.5	64.9	38.3
Share buybacks							-0.13
Cash from financing	7.75	13.5	18.7	25.2	27.5	65.8	61.9	18.3	38.5	24.3
Exchange rate effect									-0.07	0.01
Net change in cash	-1.58	2.63	7.28	9.41	8.19	7.22	13.5	-12.7	-8.97	-5.97
Free cash flow	-9.19	-10.8	-11.5	-15.8	-17.9	-50.7	-48.3	-31	-38.7	-26.1
Interest paid							1.88	4.03	3.93	3.49
Income taxes paid										0.29

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $6.63 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	58.2%	Gross profit / revenue.
Operating margin	-151.6%	Operating income / revenue.
EBITDA margin	-150.5%	EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin	-167.6%	Pre-tax income / revenue.
Net margin	-169.9%	Net income / revenue.
FCF margin	-121.3%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	-120.7%	Cash from operations / revenue.
Return on equity (ROE)	-64.8%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	-36.9%	Net income / average total assets.
Return on invested capital (ROIC)	-31.6%	Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue	49.8%	Research and development expense / revenue.
Stock-based pay / revenue	33.6%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	0.6%	Capital expenditures / revenue.
D&A / revenue	1.1%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	-17.3%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	-6.8%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	24.2%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	-4.5%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	9.5%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	38.2%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
EPS growth, 1y	-17.5%	EPS vs the same period a year earlier. Only from a positive base.
EPS CAGR, 3y	-41.7%	Compound annual growth of eps over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
EPS CAGR, 5y	-34.0%	Compound annual growth of eps over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	-5.7%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	-5.3%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	19.3%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	-7.4%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	-2.6%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	25.5%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	62.4%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	50.2%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	68.1%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	2.31x	Current assets / current liabilities.
Quick ratio	1.46x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	1.46x	(Cash + short-term investments) / current liabilities.
Debt / equity	0.56x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	32.2%	Total debt / total assets.
Liabilities / assets	43.0%	Total liabilities / total assets.
Net debt	$17.1M	Total debt - cash - short-term investments. Negative means more cash than debt.
Interest coverage	-7.03x	Operating income / interest expense.
Working capital	$12.5M	Current assets - current liabilities.
Goodwill and intangibles / assets	75.0%	(Goodwill + intangible assets) / total assets.
Tangible book value	-$17.3M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.22x	Revenue / average total assets.
Fixed asset turnover	41.7x	Revenue / average property, plant and equipment.
Inventory turnover	2.36x	Cost of revenue / average inventory.
Days inventory	154 days	365 x average inventory / cost of revenue.
Days payables	132 days	365 x average accounts payable / cost of revenue.

Per share

Metric	Value	How it is calculated
EPS, diluted	-$3.82	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$2.25	Revenue / diluted weighted shares.
FCF per share	-$2.73	Free cash flow / diluted weighted shares.
Operating cash flow per share	-$2.71	Cash from operations / diluted weighted shares.
Book value per share	$7.50	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	-$2.36	Tangible book value / shares outstanding.
Cash per share	$1.90	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$65.0M	Share price x shares outstanding.
Enterprise value	$82.1M	Market cap + total debt - cash - short-term investments.
P/S	3.09x	Market cap / revenue.
P/B	1.18x	Market cap / shareholders' equity. Only when equity is positive.
EV/Sales	3.91x	Enterprise value / revenue.
FCF yield	-39.2%	Free cash flow / market cap.
Earnings yield	-54.9%	Net income / market cap (the inverse of P/E).

What was DarioHealth Corp.'s revenue in fiscal 2025?

DarioHealth Corp. reported revenue of $22.4M for fiscal 2025, 17.3% lower than the year before.

Was DarioHealth Corp. profitable in fiscal 2025?

No. It reported a net loss of $41.7M.

How much free cash flow did DarioHealth Corp. generate in fiscal 2025?

Cash from operations of $25.9M minus capital expenditures of $142.0K left free cash flow of -$26.1M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to DarioHealth Corp.